Molecular biomarkers as predictors of response to neoadjuvant chemoradiation therapy in rectal cancer Journal Article

  


Authors: Milgrom, S. A.; Garcia-Aguilar, J.
Article Title: Molecular biomarkers as predictors of response to neoadjuvant chemoradiation therapy in rectal cancer
Abstract: The standard management of locally advanced rectal cancer includes neoadjuvant chemoradiation therapy (CRT) with 5-fluorouracil (5-FU) and concurrent pelvic irradiation (RT) to 45-50.4. Gy. This regimen results in downstaging in approximately 60% of patients and a pathological complete response (pCR) in 20%. Response to CRT is associated with improved rates of survival, local control, and sphincter preservation. However, some tumors are completely resistant to CRT; thus, non-responding patients experience only the toxicity of this treatment without any of its benefits. The ability to predict an individual patient's response to CRT would enable delivery of more effective treatment: patients predicted to respond would be directed to undergo CRT, while those predicted not to respond would be guided to alternative therapies or primary surgical resection. Molecular biomarkers have significant potential for predicting tumor regression. Furthermore, they may represent novel targets for therapeutic agents. Many studies have yielded promising results; to date, however, they have often lacked reproducibility. This review aims to summarize our current understanding of molecular biomarkers that may be used to predict response to CRT in rectal cancer. © 2013 Elsevier Inc.
Keywords: vasculotropin; cancer survival; protein expression; treatment response; overall survival; sequence analysis; fluorouracil; patient selection; drug targeting; capecitabine; adjuvant therapy; cancer radiotherapy; disease free survival; cancer staging; genetic analysis; colorectal cancer; ki 67 antigen; antigen expression; reproducibility; protein bcl 2; apoptosis; microrna; gene expression; oxygen; epidermal growth factor receptor; tumor regression; cetuximab; protein p53; survivin; prediction; irinotecan; panitumumab; hypoxia; rna; tumor suppressor gene; dna; carbonate dehydratase ix; microarray analysis; folinic acid; microsatellite instability; radiosensitivity; dna microarray; cyclin dependent kinase inhibitor 1a; oncogene k ras; cancer control; thymidylate synthase; k ras protein; cell cycle regulation; tumor vascularization; rectum cancer; hypoxia inducible factor 1alpha; rectum resection; anus sphincter; protein bax; 5,10 methylenetetrahydrofolate reductase (fadh2); gimeracil plus oteracil potassium plus tegafur; high throughput sequencing
Journal Title: Seminars in Colon and Rectal Surgery
Volume: 24
Issue: 3
ISSN: 1043-1489
Publisher: Elsevier Inc.  
Date Published: 2013-09-01
Start Page: 119
End Page: 124
Language: English
DOI: 10.1053/j.scrs.2013.03.003
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84882974158&partnerID=40&md5=6e069cf284f4dd033fa786f58ae6ec61
Notes: --- - "Export Date: 1 October 2013" - "CODEN: SCRSF" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Sarah Allison Milgrom
    22 Milgrom
  2. Julio Garcia Aguilar
    350 Garcia Aguilar
Related MSK Work